- Conditions
- Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
- Interventions
- Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD)
- Device · Drug
- Lead sponsor
- Nuwellis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 38
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 192
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Illness
- Interventions
- Care Project for Hospitalized Elders & Family Caregivers, Comparison Group
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 421 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Acute Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18,805 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Chicago, Illinois + 10 more
- Conditions
- Arthritis, Gouty
- Interventions
- canakinumab, dexamethasone, placebo matching canakinumab, placebo matching dexamethasone
- Biological · Drug · Other
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • New Brunswick, New Jersey
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Expressive Writing Coaching
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- COPD Exacerbation Acute
- Interventions
- AIRVO 2, the new asymmetric nasal cannula
- Device
- Lead sponsor
- Temple University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- COVID-19
- Interventions
- casirivimab+imdevimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Minute to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Stony Brook, New York • Memphis, Tennessee
- Conditions
- The Trial Will Compare Two Care Delivery Models That Are Currently Being Used in Routine Practice Settings for Acute Hospitalization
- Interventions
- Advanced Care at Home (ACH), Traditional Brick-and-Mortar Hospitalization
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more
- Conditions
- Congestive Heart Failure
- Interventions
- Aquadex system, IV diuretic
- Device · Drug
- Lead sponsor
- Nuwellis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Lombard, Illinois
- Conditions
- Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
- Interventions
- Varespladib, Placebo
- Drug
- Lead sponsor
- Ophirex, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Ventura, California • Miami, Florida • Munster, Indiana + 3 more
- Conditions
- RSV Infection
- Interventions
- EDP-938, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 31
- States / cities
- Tempe, Arizona • Fresno, California • Lomita, California + 26 more
- Conditions
- COVID-19
- Interventions
- VIR-7831, Placebo, Remdesivir
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 74
- States / cities
- Tucson, Arizona • Fresno, California • Loma Linda, California + 50 more
- Conditions
- Community-acquired Pneumonia, COPD Exacerbation Acute
- Interventions
- neuromuscular electrical stimulation (NMES)
- Device
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure，Congestive, Heart Failure; With Decompensation, Heart Failure Acute, Heart Failure With Reduced Ejection Fraction
- Interventions
- BAMS-HF Program
- Behavioral
- Lead sponsor
- VA Eastern Colorado Health Care System
- Federal
- Eligibility
- 55 Years to 100 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Heart Failure, Acute Decompensated Heart Failure
- Interventions
- Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor
- Combination Product
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
- Interventions
- ornithine phenylacetate, placebo intravenous infusion
- Drug
- Lead sponsor
- Ocera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more
- Conditions
- COVID-19
- Interventions
- MP0420, Placebo, Remdesivir
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 73
- States / cities
- Tucson, Arizona • Chula Vista, California • Fresno, California + 52 more
- Conditions
- Bronchiolitis Acute
- Interventions
- Moderate-Resource Implementation Strategy, High-Resource Implementation Strategy
- Other
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 0 Months to 24 Months
- Enrollment
- 2,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more
- Conditions
- Hypoxemia, Severe Acute Respiratory Syndrome
- Interventions
- Corticosteroid
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
- Interventions
- ZTI-01, Piperacillin-tazobactam
- Drug
- Lead sponsor
- Nabriva Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Pensacola, Florida • Augusta, Georgia • Columbus, Georgia + 3 more
- Conditions
- Heart Failure, Acute Heart Failure
- Interventions
- Finerenone, Placebo
- Drug
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 72 more
- Conditions
- COVID-19, Pneumonia
- Interventions
- LY3127804, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 10 more
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome (ARDS)
- Interventions
- Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more
- Conditions
- Respiratory Tract Infections
- Interventions
- Rilematovir, Rilematovir X mg/kg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 1 Day to 5 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Jackson, Mississippi • The Bronx, New York + 2 more